Baird Maintains Neutral on Regeneron Pharmaceuticals, Raises Price Target to $875

Benzinga · 2d ago
Baird analyst Brian Skorney maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Neutral and raises the price target from $761 to $875.